Martin Samuel Bates 4

Accession 0001415889-22-008608

CIK 0000744218other

View on SEC.gov Company Profile

Filed

Aug 14, 8:00 PM ET

Accepted

Aug 15, 4:16 PM ET

Size

22.4 KB

Accession

0001415889-22-008608

Insider Transaction Report

Form 4

Period: 2022-08-11

Celldex Therapeutics, Inc.CLDX

Martin Samuel Bates

SVP AND CFO

Transactions

Exercise/Conversion
Common Stock
2022-08-11$9.02/sh+2,453$22,117→ 26,831 total
Sale
Common Stock
2022-08-11$37.04/sh−2,453$90,856→ 24,378 total
Exercise/Conversion
Common Stock
2022-08-12$9.02/sh+3,876$34,948→ 28,254 total
Exercise/Conversion
Common Stock
2022-08-12$2.78/sh+13,671$38,005→ 41,925 total
Sale
Common Stock
2022-08-12$36.76/sh−14,261$524,304→ 27,664 total
Sale
Common Stock
2022-08-12$35.38/sh−2,065$73,053→ 25,599 total
Sale
Common Stock
2022-08-12$34.62/sh−1,221$42,272→ 24,378 total
Exercise/Conversion
Incentive Stock Option (Right to Buy)
2022-08-11−2,453→ 7,077 total
Exercise: $9.02Exp: 2028-06-13→ Common Stock (2,453 underlying)
Exercise/Conversion
Incentive Stock Option (Right to Buy)
2022-08-12−3,876→ 3,201 total
Exercise: $9.02Exp: 2028-06-13→ Common Stock (3,876 underlying)
Exercise/Conversion
Incentive Stock Option (Right to Buy)
2022-08-12−13,671→ 10,750 total
Exercise: $2.78Exp: 2029-06-19→ Common Stock (13,671 underlying)

Footnotes (6)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.26 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.23 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.82 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.31 to $34.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
[F5]As of June 13, 2022, the option is fully vested.
[F6]25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Documents

1 file

4
form4-08152022_010833.xmlPrimary

Issuer

Celldex Therapeutics, Inc.

CIK 0000744218

→

Entity typeother

Related Parties

filerCIK 0001709024

Filing Metadata

Form type: 4
Filed: Aug 14, 8:00 PM ET
Accepted: Aug 15, 4:16 PM ET
Size: 22.4 KB

View on SEC.gov